Eficacia de los bacteriófagos para el tratamiento de infecciones recalcitrantes Reportes de casos modernos
Article Sidebar
Publicado
sep 28, 2023
##plugins.pubIds.doi.readerDisplayName##
https://doi.org/10.36677/medicinainvestigacion.v11i2.20910
Main Article Content
Juan Martín Talavera González
http://orcid.org/0000-0002-6579-2251
Martín Talavera-Rojas
http://orcid.org/0000-0003-0908-985X
Nydia Edith Reyes-Rodríguez
http://orcid.org/0000-0002-4307-8161
Vicente Vega-Sánchez
http://orcid.org/0000-0003-3466-8677
Celene Salgado Miranda
http://orcid.org/0000-0001-8014-241X
http://orcid.org/0000-0002-6579-2251
Martín Talavera-Rojas
http://orcid.org/0000-0003-0908-985X
Nydia Edith Reyes-Rodríguez
http://orcid.org/0000-0002-4307-8161
Vicente Vega-Sánchez
http://orcid.org/0000-0003-3466-8677
Celene Salgado Miranda
http://orcid.org/0000-0001-8014-241X
Resumen
Resumen
Con el surgimiento de β-lactamasas de espectro extendido (BLEE) y cepas bacterianas resistentes a múltiples fármacos existe una necesidad médica urgente para el tratamiento eficaz de múltiples infecciones de origen bacteriano. Los bacteriófagos, desde su descubrimiento a principios del siglo XX, fueron reconocidos como una propuesta terapéutica para enfrentar infecciones generadas por bacterias; algunos gobiernos y compañías farmacéuticas comienzan a reevaluar el uso terapéutico de estos “comedores de bacterias”. Sin embargo, existe poca revisión bibliográfica sobre la aplicación clínica de los fagos. En este trabajo, se revisan algunos informes modernos de la aplicación de la terapia fágica para el tratamiento exitoso de infecciones ocasionadas por bacterias formadoras de biopelículas en las que la terapia con antibióticos ha fallado. También se mencionan empresas e institutos internacionales que comercializan, investigan y desarrollan productos con fagos para uso humano. La terapia con fagos ofrece una alternativa prometedora para combatir las bacterias multirresistentes y reducir las infecciones letales. Los nuevos conocimientos sobre la seguridad y la eficacia de los fagos son cruciales para comprender mejor su aplicación.
Article Details
Como citar
TALAVERA GONZÁLEZ, Juan Martín et al.
Eficacia de los bacteriófagos para el tratamiento de infecciones recalcitrantes.
Medicina e Investigación Universidad Autónoma del Estado de México, [S.l.], v. 11, n. 2, p. 64-70, sep. 2023.
ISSN 2594-0600.
Disponible en: <https://medicinainvestigacion.uaemex.mx/article/view/20910>. Fecha de acceso: 18 ago. 2026
doi: https://doi.org/10.36677/medicinainvestigacion.v11i2.20910.
Sección
Artículos de revisión
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Citas
Górski A, Miedzybrodzki R, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Rogóz P, et al. Phage therapy: Combating infections with potential for evol-ving from merely a treatment for complications to targeting diseases. Fron-tiers in Microbiology. 2016; 7.
Pirnay JP. Phage Therapy in the Year 2035. Front Microbiol. 2020; 3 (11).
Abedon ST, Danis-Wlodarczyk KM, Alves DR. Phage therapy in the 21st cen-tury: Is there modern, clinical evidence of phage-mediated efficacy? Phar-maceuticals. 2021; 14 (11).
Ferry T, Kolenda C, Briot T, Souche A, Lustig S, Josse J, et al. Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infec-tion. Viruses [Internet]. 2021; 13 (12). Disponible en: /pmc/articles/PMC8708067/
Brives C, Pourraz J. Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun [Internet]. 2020. Disponible en: https://doi.org/10.1057/s41599-020-0478-4
McCallin S, Sacher JC, Zheng J, Chan BK. Current State of Compassionate Phage Therapy. Viruses [Internet]. 2019; 11 (4). Disponible en: https://pub-med.ncbi.nlm.nih.gov/31013833/
Aminov R, Caplin J, Chanishvili N, Coffey A, Cooper I, de Vos D, et al. Appli-cation of bacteriophages. Microbiol. 2017; 38 (2): 63.
Ferry T, Leboucher G, Fevre C, Herry Y, Conrad A, Josse J, et al. Salvage Debridement, Antibiotics and Implant Retention (‘DAIR’) With Local Injec-tion of a Selected Cocktail of Bacteriophages: Is It an Option for an Elderly Patient With Relapsing Staphylococcus aureus Prosthetic-Joint Infection? Open Forum Infect Dis. 2018; 5 (11).
Ferry T, Kolenda C, Batailler C, Gaillard R, Gustave CA, Lustig S, et al. Case Report: Arthroscopic “Debridement Antibiotics and Implant Retention” With Local Injection of Personalized Phage Therapy to Salvage a Relapsing Pseudomonas Aeruginosa Prosthetic Knee Infection. Front Med [Internet]. 2021; 8: 569159. Disponible en: /pmc/articles/PMC8132876/
Cano EJ, Caflisch KM, Bollyky PL, van Belleghem JD, Patel R, Fackler J, et al. Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneu-moniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity. Clin Infect Dis [Internet]. 2021; 73 (1): e144. Disponible en: /pmc/articles/PMC8246933/
Doub JB, Ng VY, Wilson E, Corsini L, Chan BK. Successful Treatment of a Recalcitrant Staphylococcus epidermidis Prosthetic Knee Infection with Intraoperative Bacteriophage Therapy. Pharmaceuticals [Internet]. 2021; 14 (3): 231. Disponible en: /pmc/articles/PMC7998749/
Ramirez-Sanchez C, Gonzales F, Buckley M, Biswas B, Henry M, Deschenes M v., et al. Successful Treatment of Staphylococcus aureus Prosthetic Joint Infection with Bacteriophage Therapy. Viruses [Internet]. 2021; 13 (6). Dis-ponible en: /pmc/articles/PMC8233819/
Svoboda Elizabeth. Phages could help when antibiotics fail. Nature. 2020; 583: S8–9.
Gainey AB, Burch AK, Brownstein MJ, Brown DE, Fackler J, Horne B, et al. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020; 55 (11): 2990–2994.
Hoyle N, Zhvaniya P, Balarjishvili N, Bolkvadze D, Nadareishvili L, Nizharadze D, et al. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Res Microbiol. 2018; 169 (9): 540–2.
Lebeaux D, Merabishvili M, Caudron E, Lannoy D, van Simaey L, Duyvejonck H, et al. A Case of Phage Therapy against Pandrug-Resistant Achromobac-ter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. Viruses [Internet]. 2021; 13 (1). Disponible en: /pmc/articles/PMC7824836/
Law N, Logan C, Yung G, Furr CLL, Le-hman SM, Morales S, et al. Successful adjunctive use of bacteriophage thera-py for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019; 47 (4): 665–668.
Wu N, Dai J, Guo M, Li J, Zhou X, Li F, et al. Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 pa-tients. Emerg Microbes Infect [Inter-net]. 2021. Disponible en: https://doi.org/10.1080/22221751.2021.1902754
Marza JAS, Soothill JS, Boydell P, Colly-ns TA. Multiplication of therapeutically administered bacteriophages in Pseu-domonas aeruginosa infected patients. Burns. 2006; 32 (5): 644–646.
Gupta P, Singh HS, Shukla VK, Nath G, Bhartiya SK. Bacteriophage The-rapy of Chronic Nonhealing Wound: Clinical Study. International Journal of Lower Extremity Wounds. 2019; 18 (2): 171–175.
Markoishvili K, Tsitlanadze G, Katsa-rava R, Glenn Morris J, Sulakvelidze A, Alexander Sulakvelidze C. Phar-macology and Therapeutics A no-vel sustained-release matrix based on biodegradable polyesteramides and impregnated with bacteriopha-ges and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly hea-ling wounds. Int J Dermatol. 2002; 41: 453–458.
Jikia D, Chkhaidze N, Imedashvi-li E, Mgaloblishvili I, Tsitlanadze G, Katsarava R, et al. The use of a no-vel biodegradable preparation ca-pable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multi-drug-resistant Staphylococcus au-reus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol. 2005; 30 (1): 23–26.
Corbellino M, Kieffer N, Kutatela-dze M, Balarjishvili N, Leshkasheli L, Askilashvili L, et al. Eradication of a multi-drug resistant, carbapenema-se-producing Klebsiella pneumoniae isolate following oral and intra-rectal therapy with a custom-made, lytic bacteriophage preparation. Clinical Infec-tious Diseases [Internet]. 2020; 20 (9): 1998–2001. Disponible en: https://aca-demic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz782/5550234
Johri AV, Johri P, Hoyle N, Pipia L, Nadareishvili L, Nizharadze D. Case Re-port: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multi-ple Failed Antibiotic Treatments. Front Pharmacol [Internet]. 2021; 12. Dis-ponible en: /pmc/articles/PMC8222915/
Kuipers S, Ruth MM, Mientjes M, de Sévaux RGL, van Ingen J. A Dutch Case Report of Successful Treatment of Chronic Relapsing Urinary Tract Infec-tion with Bacteriophages in a Renal Transplant Patient. Antimicrob Agents Chemother [Internet]. 2020; 64 (1). Disponible en: /pmc/articles/PMC7187595/26. Rostkowska OM, Międzybrodzki R, Miszewska-Szyszkowska D, Górski A, Durlik M. Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy. Transplant Infectious Disease. 2021; 23 (1).
Pirnay JP. Phage Therapy in the Year 2035. Front Microbiol. 2020; 3 (11).
Abedon ST, Danis-Wlodarczyk KM, Alves DR. Phage therapy in the 21st cen-tury: Is there modern, clinical evidence of phage-mediated efficacy? Phar-maceuticals. 2021; 14 (11).
Ferry T, Kolenda C, Briot T, Souche A, Lustig S, Josse J, et al. Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infec-tion. Viruses [Internet]. 2021; 13 (12). Disponible en: /pmc/articles/PMC8708067/
Brives C, Pourraz J. Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun [Internet]. 2020. Disponible en: https://doi.org/10.1057/s41599-020-0478-4
McCallin S, Sacher JC, Zheng J, Chan BK. Current State of Compassionate Phage Therapy. Viruses [Internet]. 2019; 11 (4). Disponible en: https://pub-med.ncbi.nlm.nih.gov/31013833/
Aminov R, Caplin J, Chanishvili N, Coffey A, Cooper I, de Vos D, et al. Appli-cation of bacteriophages. Microbiol. 2017; 38 (2): 63.
Ferry T, Leboucher G, Fevre C, Herry Y, Conrad A, Josse J, et al. Salvage Debridement, Antibiotics and Implant Retention (‘DAIR’) With Local Injec-tion of a Selected Cocktail of Bacteriophages: Is It an Option for an Elderly Patient With Relapsing Staphylococcus aureus Prosthetic-Joint Infection? Open Forum Infect Dis. 2018; 5 (11).
Ferry T, Kolenda C, Batailler C, Gaillard R, Gustave CA, Lustig S, et al. Case Report: Arthroscopic “Debridement Antibiotics and Implant Retention” With Local Injection of Personalized Phage Therapy to Salvage a Relapsing Pseudomonas Aeruginosa Prosthetic Knee Infection. Front Med [Internet]. 2021; 8: 569159. Disponible en: /pmc/articles/PMC8132876/
Cano EJ, Caflisch KM, Bollyky PL, van Belleghem JD, Patel R, Fackler J, et al. Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneu-moniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity. Clin Infect Dis [Internet]. 2021; 73 (1): e144. Disponible en: /pmc/articles/PMC8246933/
Doub JB, Ng VY, Wilson E, Corsini L, Chan BK. Successful Treatment of a Recalcitrant Staphylococcus epidermidis Prosthetic Knee Infection with Intraoperative Bacteriophage Therapy. Pharmaceuticals [Internet]. 2021; 14 (3): 231. Disponible en: /pmc/articles/PMC7998749/
Ramirez-Sanchez C, Gonzales F, Buckley M, Biswas B, Henry M, Deschenes M v., et al. Successful Treatment of Staphylococcus aureus Prosthetic Joint Infection with Bacteriophage Therapy. Viruses [Internet]. 2021; 13 (6). Dis-ponible en: /pmc/articles/PMC8233819/
Svoboda Elizabeth. Phages could help when antibiotics fail. Nature. 2020; 583: S8–9.
Gainey AB, Burch AK, Brownstein MJ, Brown DE, Fackler J, Horne B, et al. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020; 55 (11): 2990–2994.
Hoyle N, Zhvaniya P, Balarjishvili N, Bolkvadze D, Nadareishvili L, Nizharadze D, et al. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Res Microbiol. 2018; 169 (9): 540–2.
Lebeaux D, Merabishvili M, Caudron E, Lannoy D, van Simaey L, Duyvejonck H, et al. A Case of Phage Therapy against Pandrug-Resistant Achromobac-ter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. Viruses [Internet]. 2021; 13 (1). Disponible en: /pmc/articles/PMC7824836/
Law N, Logan C, Yung G, Furr CLL, Le-hman SM, Morales S, et al. Successful adjunctive use of bacteriophage thera-py for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019; 47 (4): 665–668.
Wu N, Dai J, Guo M, Li J, Zhou X, Li F, et al. Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 pa-tients. Emerg Microbes Infect [Inter-net]. 2021. Disponible en: https://doi.org/10.1080/22221751.2021.1902754
Marza JAS, Soothill JS, Boydell P, Colly-ns TA. Multiplication of therapeutically administered bacteriophages in Pseu-domonas aeruginosa infected patients. Burns. 2006; 32 (5): 644–646.
Gupta P, Singh HS, Shukla VK, Nath G, Bhartiya SK. Bacteriophage The-rapy of Chronic Nonhealing Wound: Clinical Study. International Journal of Lower Extremity Wounds. 2019; 18 (2): 171–175.
Markoishvili K, Tsitlanadze G, Katsa-rava R, Glenn Morris J, Sulakvelidze A, Alexander Sulakvelidze C. Phar-macology and Therapeutics A no-vel sustained-release matrix based on biodegradable polyesteramides and impregnated with bacteriopha-ges and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly hea-ling wounds. Int J Dermatol. 2002; 41: 453–458.
Jikia D, Chkhaidze N, Imedashvi-li E, Mgaloblishvili I, Tsitlanadze G, Katsarava R, et al. The use of a no-vel biodegradable preparation ca-pable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multi-drug-resistant Staphylococcus au-reus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol. 2005; 30 (1): 23–26.
Corbellino M, Kieffer N, Kutatela-dze M, Balarjishvili N, Leshkasheli L, Askilashvili L, et al. Eradication of a multi-drug resistant, carbapenema-se-producing Klebsiella pneumoniae isolate following oral and intra-rectal therapy with a custom-made, lytic bacteriophage preparation. Clinical Infec-tious Diseases [Internet]. 2020; 20 (9): 1998–2001. Disponible en: https://aca-demic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz782/5550234
Johri AV, Johri P, Hoyle N, Pipia L, Nadareishvili L, Nizharadze D. Case Re-port: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multi-ple Failed Antibiotic Treatments. Front Pharmacol [Internet]. 2021; 12. Dis-ponible en: /pmc/articles/PMC8222915/
Kuipers S, Ruth MM, Mientjes M, de Sévaux RGL, van Ingen J. A Dutch Case Report of Successful Treatment of Chronic Relapsing Urinary Tract Infec-tion with Bacteriophages in a Renal Transplant Patient. Antimicrob Agents Chemother [Internet]. 2020; 64 (1). Disponible en: /pmc/articles/PMC7187595/26. Rostkowska OM, Międzybrodzki R, Miszewska-Szyszkowska D, Górski A, Durlik M. Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy. Transplant Infectious Disease. 2021; 23 (1).